Abstract:Introduction: Polycystic ovarian syndrome (PCOS) is a leading cause of female subfertility worldwide, however due to the heterogeneity of the disorder, the criteria for diagnosis remains subject to conjecture. In the present study, we evaluate the utility of serum Anti-Müllerian Hormone (AMH) in the diagnosis of menstrual disturbance due to PCOS.Method: Menstrual cycle length, serum AMH, gonadotropin and sex-hormone levels, total antral follicle count (AFC), body mass index (BMI) and ovarian morphology on ultrasound were analyzed in a cohort of 187 non-obese women, aged 18–35 years, screened for participation in a clinical trial of fertility treatment between 2013 and 2016 at a tertiary reproductive endocrine center.Results: Serum AMH was higher in women with menstrual disturbance when compared to those with regular cycles (65.6 vs. 34.8 pmol/L; P < 0.0001). The odds of menstrual disturbance was increased 28.5-fold (95% CI 3.6–227.3) in women with serum AMH >60 pmol/L, in comparison to those with an AMH < 15 pmol/L. AMH better discriminated women with menstrual disturbance (area under ROC 0.77) from those with regular menstrual cycles than AFC (area under ROC 0.67), however the combination of the two markers increased discrimination than either measure alone (0.83; 95% CI 0.77–0.89). Serum AMH was higher in women with all three cardinal features of PCOS (menstrual disturbance, hyperandrogenism, polycystic ovarian morphology) when compared to women with none of these features (65.6 vs. 14.6 pmol/L; P < 0.0001). The odds of menstrual disturbance were increased by 10.7-fold (95% CI 2.4–47.1) in women with bilateral polycystic morphology ovaries than those with normal ovarian morphology. BMI was a stronger predictor of free androgen index (FAI) than either AMH or AFC.Conclusion: Serum AMH could serve as a useful biomarker to indicate the risk of menstrual disturbance due to PCOS. Women with higher AMH levels had increased rates of menstrual disturbance and an increased number of features of PCOS.

Research progress of role of AMH in polycystic ovarian syndrome

The Role of Anti-Müllerian Hormone in the Pathogenesis and Pathophysiological Characteristics of Polycystic Ovary Syndrome

The role of AMH in the pathophysiology of polycystic ovarian syndrome

Relationship Between Anti-Müllerian Hormone and Polycystic Ovary Syndrome

Role of Anti-Müllerian Hormone and Testosterone in Follicular Growth: a Cross-Sectional Study.

The Anti-Müllerian Hormone and Polycystic Ovary Syndrome

Anti-Müllerian Hormone in Pathogenesis, Diagnostic and Treatment of PCOS

Analysis of serum anti-Müllerian hormone levels in the main phenotypes of polycystic ovary syndrome

Advances in Molecular Genetic Study on PCOS

Research progress on the mechanism of abnormal endometrial receptivity in women with polycystic ovary syndrome

Hearing results in tympanic membrane footplate and malleus-footplate assemblies.

[Research Progress in the Pathogenesis of Polycystic Ovary Syndrome]

Relationship Between Polymorphism of Anti-Mullerian Hormone,anti-Mullerian Hormone Receptor Type Ⅱ and Polycystic Ovary Syndrome

Haplotype Analysis of Single Nucleotide Polymorphisms in Anti-Müllerian Hormone Gene in Chinese PCOS Women

Anti-Müllerian Hormone Levels in Women with Polycystic Ovarian Syndrome Compared with Normal Women of Reproductive Age in China

The advance on the relationship between genetic polymorphism and the pathogenesis of PCOS

Hierarchically distributed multicast management architecture in ATM networks

Research Advances in the Role of Inflammatory Factors in Polycystic Ovary Syndrome

Anti-Müllerian hormone (AMH) in the Diagnosis of Menstrual Disturbance Due to Polycystic Ovarian Syndrome

An Update on the Progress of Endometrial Receptivity in Women with Polycystic Ovary Syndrome

Advances in Mitochondrial Dysfunction in Women with Polycystic Ovary Syndrome